# FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

Study · id `cardio:ct-nct06409364` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06409364](<https://clinicaltrials.gov/study/NCT06409364>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06409364

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 524 participants.

## Technical summary

Registry record NCT06409364. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-13 (actual); primary completion 2029-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 524 participants (planned count; ClinicalTrials.gov record NCT06409364, source copy `cardio:ctgov-nct06409364-2025-12-16`, retrieved 2026-10-31)
- Started: 2025-08-13 (actual) (ClinicalTrials.gov record NCT06409364, source copy `cardio:ctgov-nct06409364-2025-12-16`, retrieved 2026-10-31)
- Primary completion: 2029-07-31 (anticipated) (ClinicalTrials.gov record NCT06409364, source copy `cardio:ctgov-nct06409364-2025-12-16`, retrieved 2026-10-31)
- Completion: 2030-07-31 (anticipated) (ClinicalTrials.gov record NCT06409364, source copy `cardio:ctgov-nct06409364-2025-12-16`, retrieved 2026-10-31)
- Countries: Australia; New Zealand (ClinicalTrials.gov record NCT06409364, source copy `cardio:ctgov-nct06409364-2025-12-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06409364-2025-12-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage
- Acronym: FLASH
- Condition: Aneurysmal Subarachnoid Hemorrhage
- Intervention (Drug): Fludrocortisone
- Intervention (Drug): Placebo
- Lead sponsor: The George Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Subarachnoid hemorrhage (`cardio:subarachnoid-hemorrhage`)
- Registry lists this organization as the lead sponsor: The George Institute for Global Health (`core:george-institute`)

## Provenance

Content hash: 193e6d37303159cd044f04e1f3b2a0efcad7d5518344cbb233626e0043ebff68
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
